How do you address logistic barriers related to blinatumomab when treating relapsed B-ALL?
For example, if patients are unable to receive continuous infusion from home health agencies, or if prolonged hospitalization is cost-prohibitive.
Answer from: Medical Oncologist at Academic Institution
This is a very challenging issue that speaks to an incredibly important aspect of delivering not only this drug but others like it. Despite the strong evidence that supports the use of blinatumomab in a variety of clinical scenarios for patients with B-cell ALL [e.g., Gökbuget et al., PMID 2935...
Sign in or Register to read more
Answer from: at Academic Institution
I agree with all of Dr. @Cassaday's answers. We have found it easier than expected to provide blinatumomab for all of the children we feel could benefit from it. Some issues that came up and were dealt with:
Preauthorization: for patients who meet the approved indication, MRD positivity after ind...